1. Determination of debrisoquine oxidation phenotype was carried out in 119 healthy subjects, 135 patients with chronic bronchitis and 153 patients with lung cancer, all of Caucasian origin. 2. A non-Gaussian distribution of the log D/HD ratio was observed in the three groups. 3. Assuming an antimode of 1.12, the proportion of PMs was found to be 6.7% in healthy subjects, 8.9% in chronic bronchitics and 6.5% in patients with lung cancer. These differences were not significant. 4. The presence of a lung tumour itself had no influence on phenotype in a group of 14 patients who were phenotyped before and after surgery. 5. We conclude that a link between debrisoquine phenotype and lung cancer is unlikely.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1368471 | PMC |
| http://dx.doi.org/10.1111/j.1365-2125.1991.tb05575.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patient-Centered Physical Activity Intervention in Lung Cancer Patients: A Clinical Severity and Functional Capacity Systematic Review and Meta-analysis.
Cancer Nurs
January 2025
Author Affiliations: Departments of Physiotherapy (Drs Heredia Ciuró, Martín Núñez, Navas Otero, Calvache Mateo, Torres Sánchez, and Valenza) and Nursing (Dr Granados Santiago), Faculty of Health Sciences, University of Granada, Granada, Spain.
Background: Increasing physical activity levels is a significant unmet need in cancer survivors, and it can likely be enhanced through a better understanding of the interventions developed. Some studies on patient-centered physical activity interventions have shown promising results in increasing daily activity levels among lung cancer survivors. However, the programs present a high heterogeneity, and there is no consensus on the parameters and their effectiveness.
View Article and Find Full Text PDFNRG1 Fusions: The New Kid on the Block.
Curr Oncol Rep
January 2025
Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road NW, Washington, DC, 20007, USA.
Purpose Of Review: Neuregulin 1 (NRG1) fusions are rare but actionable oncogenic drivers that occur in a variety of tumor types, including non-small cell lung cancer (NSCLC). These fusions lead to pathophysiologic activation of HER signaling pathways, promoting tumor growth, invasion, and metastasis. Current evidence suggests that NRG1 fusion-positive NSCLC does not respond well to conventional treatments such as immunotherapy and chemotherapy.
View Article and Find Full Text PDFMinimally invasive biomarkers for triaging lung nodules-challenges and future perspectives.
Cancer Metastasis Rev
January 2025
Saliva and Liquid Biopsy Translational Laboratory, Institute for Biomedicine and Glycomics (IBG), Griffith University, Brisbane, 4111, Australia.
CT chest scans are commonly performed worldwide, either in routine clinical practice for a wide range of indications or as part of lung cancer screening programs. Many of these scans detect lung nodules, which are small, rounded opacities measuring 8-30 mm. While the concern about nodules is that they may represent early lung cancer, in screening programs, only 1% of such nodules turn out to be cancer.
View Article and Find Full Text PDFPatterns of lymph node metastasis and long-term outcomes of splenic flexure colon cancer: a descriptive study from a Japanese high-volume center.
Surg Today
January 2025
Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-Ku, Tokyo, 135-8550, Japan.
Purpose: The pattern of lymph node metastasis and the appropriate extent of lymph node dissection in splenic flexure colon cancer remain unclear. This study aimed to describe the clinical characteristics, lymph node metastasis patterns, and oncological outcomes of patients with splenic flexure colon cancer.
Methods: The data of patients with splenic flexure cancer diagnosed with pathological stages I-III were extracted from a hospital database.
Molecular mechanisms of phytoconstituents from selected Egyptian plants against non-small cell lung cancer using integrated in vitro network pharmacology and molecular docking approach.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Department of Pharmacognosy, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
Non-small cell lung cancer (NSCLC) is a widespread highly malignant type of lung cancer. Conventional chemotherapeutic drugs may be accompanied by both drug resistance and serious side effects in patients. Therefore, safer and more effective medications are urgently needed for the treatment of NSCLC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!